Celestica insider plans sale of 9,186 shares via Form 144

Celestica Inc. insider filed a Form 144 notice to sell up to 9,186 common shares through broker Canaccord Genuity on the NYSE, with an approximate sale date of 12/01/2025.

Rhea-AI Filing Summary

Celestica Inc. insider filed a Form 144 notice to sell up to 9,186 common shares through broker Canaccord Genuity on the NYSE, with an approximate sale date of 12/01/2025. The filing lists an aggregate market value of these shares of $3,163,750.26. The 9,186 shares were acquired on 12/01/2025 through restricted share unit vesting from Celestica Inc. Shares outstanding were 115,036,621 at the time referenced, providing context for the size of this planned sale.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does Celestica (CLS) disclose in this Form 144 filing?

The filing discloses that a Celestica Inc. insider plans to sell up to 9,186 common shares and provides details on how and when the sale may occur.

How many Celestica (CLS) shares are planned to be sold and through which broker?

The notice covers up to 9,186 Celestica Inc. common shares to be sold through Canaccord Genuity on the NYSE.

What is the aggregate market value of the Celestica (CLS) shares in this Form 144?

The Form 144 lists an aggregate market value of $3,163,750.26 for the 9,186 Celestica Inc. common shares covered by the notice.

When were the Celestica (CLS) shares acquired and how?

The 9,186 Celestica Inc. common shares were acquired on 12/01/2025 via restricted share unit vesting from Celestica Inc.

When is the approximate sale date for the Celestica (CLS) shares under this Form 144?

The filing states an approximate date of sale of 12/01/2025 for the planned transaction.

How many Celestica (CLS) shares were outstanding as context for this Form 144?

The Form 144 cites 115,036,621 Celestica Inc. common shares outstanding, which serves as a baseline for the size of the planned sale.

What representation does the insider make in signing this Celestica (CLS) Form 144?

By signing, the insider represents that they do not know any material adverse information about Celestica Inc.'s current or prospective operations that has not been publicly disclosed.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 12/01/2025 - 04:15 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001807647
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	CELESTICA INC.
SEC File Number	001-14832
Address of Issuer	5140 Yonge Street, Suite 1900 Toronto ONTARIO, CANADA M2N 6L7
Phone	416-448-5800
Name of Person for Whose Account the Securities are To Be Sold	Etienvre Yann L
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common Shares	Canaccord Genuity 40 Temperance Street Suite 2100 Toronto Z4 A6 M5H 0B4	9186	3163750.26	115036621	12/01/2025	NYSE

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common Shares	12/01/2025	Restricted share unit vesting	Celestica Inc.			9186	12/01/2025	N/A

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks	The filing of this Form 144 shall not be construed as an admission that the undersigned is an affiliate of the Issuer.
Date of Notice	12/01/2025
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Yann L. Etienvre
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)